Top Tweets for #TechForLicensing
#TechForLicensing: CCAMP-developed Optidrop Technology makes it easier and cheaper to study single cells encapsulated in droplets.
The platform's affordability, live data visualisation, smaller data footprint, and 'closed' system design (preventing external contamination) make OptiDrop a viable benchtop technology for widespread clinical applications.
Optidrop has game-changing downstream applications in #diagnostics, #therapeutics, #agriculture and #animalhealth.
Read more: https://t.co/99xMMbKHIk
The work has been done in collaboration with
@iitmadras and with support from @BIRAC_2012, @DBTIndia and Pratiksha Trust of @kris_sg
We are seeking interest in licensing/co-development from companies and #industry partners.
If you are interested in knowing more, please reach out to the C-CAMP Office of Technology Transfer (#OTT): 📧 [email protected]
☎️080 6718 5322
@Taslimarif @PrinSciAdvOff @DBTIndia @IndiaDST @AIMtoInnovate @NITIAayog @GoI_MeitY @meitystartuphub @ITBTGoK @JNJNews @pfizer_news @ZydusUniverse @calico @BoehringerIN @Ginkgo @IVIHeadquarters @BeckmanDx @thermofisher @Agilent @AgilentLife @BDandCo @SonyBiotechInc @BioRad @BioRadLifeSci @CytekBio @DanaherCorp @Merck @SysmexEurope @SysmexNZ @miltenyibiotec
#TechForLicensing: CCAMP-developed Optidrop technology makes it easier and cheaper to study single cells encapsulated in droplets.
The platform's affordability, live data visualisation, smaller data footprint, and 'closed' system design (preventing external contamination) make OptiDrop a viable benchtop technology for widespread clinical applications.
Optidrop has game-changing downstream applications in #diagnostics, #therapeutics, #agriculture and #animalhealth.
Read more: https://t.co/99xMMbLfxS
The work has been done in collaboration with
@iitmadras and with support from @BIRAC_2012,
@DBTIndia and Pratiksha Trust of @kris_sg
We are seeking interest in licensing/co-development from companies and #industry partners.
If you are interested in knowing more, please reach out to the C-CAMP Office of Technology Transfer (#OTT):
📧 [email protected]
☎️080 6718 5322
@Taslimarif @PrinSciAdvOff @DBTIndia @IndiaDST @AIMtoInnovate @NITIAayog @GoI_MeitY @meitystartuphub @ITBTGoK @JNJNews @pfizer_news @ZydusUniverse @calico @BoehringerIN @Ginkgo @IVIHeadquarters @BeckmanDx @thermofisher @Agilent @AgilentLife @BDandCo @SonyBiotechInc @BioRad @BioRadLifeSci @CytekBio @DanaherCorp @Merck @SysmexEurope @SysmexNZ @miltenyibiotec
#TechForLicensing: A novel synthetic bone graft that helps in bone formation in half the duration in comparison to the time taken by currently available bone substitutes.
The Problem: A single material that is bio-compatible, non-toxic, osteo-conductive, osteo-inductive, with good adherence to the host tissue and early conversion to bone is not available.
Current Scenario: Existing synthetic bone-grafts are limited by slow bone formation. Also, the cost of certain existing materials used as synthetic bone grafts is quite high.
The new synthetic bone graft is made of silica-free fluoro-phosphate ceramic doped with metal oxides.
Advantages:
*Significantly faster bone formation than silica-glass, which is the current standard of care
*Novel composite forms bone by all three known methods, i.e., osteogenesis, osteo-conduction, osteo-induction
*Can be produced by a simple industrial setup, is scalable and has a long shelf-life
We are inviting licensing interests.
To know more, please reach out to the CCAMP Office of Technology Transfer (#OTT):
📧[email protected]
☎️080 6718 5322
@Taslimarif @DBTIndia @PrinSciAdvOff @BIRAC_2012 @kris_sg
@baxter_intl @zimmerbiometIND @Medtronic @GlobusMedical @Biocomposites1 @Biomatlante @OrthocellLtd
#TechForLicensing: CCAMP-developed Optidrop technology makes it easier and cheaper to study single cells encapsulated in droplets.
The platform's affordability, live data visualisation, smaller data footprint, and 'closed' system design (preventing external contamination) make OptiDrop a viable benchtop technology for widespread clinical applications.
Optidrop has game-changing downstream applications in #diagnostics, #therapeutics, #agriculture and #animalhealth.
Read more: https://t.co/99xMMbKHIk
The work has been done in collaboration with @iitmadras and with support from @BIRAC_2012,
@DBTIndia and Pratiksha Trust of @kris_sg
We are seeking interest in licensing/co-development from companies and #industry partners.
If you are interested in knowing more, please reach out to the C-CAMP Office of Technology Transfer (#OTT):
📧 [email protected]
☎️080 6718 5322
@Taslimarif @PrinSciAdvOff @DBTIndia @IndiaDST @AIMtoInnovate @NITIAayog @GoI_MeitY @meitystartuphub @ITBTGoK
@JNJNews @pfizer_news @ZydusUniverse @calico @BoehringerIN @Ginkgo @IVIHeadquarters @BeckmanDx @thermofisher @Agilent @AgilentLife @BDandCo @SonyBiotechInc @BioRad @BioRadLifeSci @CytekBio @DanaherCorp @Merck @SysmexEurope @SysmexNZ @miltenyibiotec
#TechForLicensing: CCAMP-developed Optidrop technology makes it easier and cheaper to study single cells encapsulated in droplets.
The platform's affordability, live data visualisation, smaller data footprint, and 'closed' system design (preventing external contamination) make OptiDrop a viable benchtop technology for widespread clinical applications.
Optidrop has game-changing downstream applications in #diagnostics, #therapeutics, #agriculture and #animalhealth.
Read more: https://t.co/99xMMbKHIk
The work has been done in collaboration with @iitmadras and with support from @BIRAC_2012, @DBTIndia and Pratiksha Trust of @kris_sg.
We are seeking interest in licensing/co-development from companies and #industry partners.
If you are interested in knowing more, please reach out to the C-CAMP Office of Technology Transfer (#OTT):
📧 [email protected]
☎️080 6718 5322
@Taslimarif @PrinSciAdvOff @DBTIndia @IndiaDST
@AIMtoInnovate @NITIAayog @GoI_MeitY @meitystartuphub @ITBTGoK
@JNJNews @pfizer_news @ZydusUniverse @calico @BoehringerIN @Ginkgo @IVIHeadquarters
@BeckmanDx @thermofisher @Agilent @AgilentLife @BDandCo @SonyBiotechInc @BioRad @BioRadLifeSci @CytekBio @DanaherCorp @Merck @SysmexEurope @SysmexNZ @miltenyibiotec
#TechForLicensing: A novel synthetic bone graft that helps in bone formation in half the duration in comparison to the time taken by currently available bone substitutes.
The Problem: A single material that is bio-compatible, non-toxic, osteo-conductive, osteo-inductive, with good adherence to the host tissue and early conversion to bone is not available.
Current Scenario: Existing synthetic bone-grafts are limited by slow bone formation. Also, the cost of certain existing materials used as synthetic bone grafts is quite high.
The new synthetic bone graft is made of silica-free fluoro-phosphate ceramic doped with metal oxides.
Advantages:
* Significantly faster bone formation than silica-glass, which is the current standard of care
* Novel composite forms bone by all three known methods, i.e., osteogenesis, osteo-conduction, osteo-induction
* Can be produced by a simple industrial setup, is scalable and has a long shelf-life
We are inviting licensing interests.
To know more, please reach out to the CCAMP Office of Technology Transfer (#OTT):
📧[email protected]
☎️080 6718 5322
@Taslimarif @DBTIndia @PrinSciAdvOff @kris_sg
@BIRAC_2012 @zimmerbiometIND @Medtronic @GlobusMedical
#TechForLicensing: Researchers at CCAMP, in collaboration with @DBT_CDFD, have successfully developed & tested in mice a novel topical formulation that shows significantly accelerated complex wound healing through promoting regeneration of tissues!
The Problem: The risk factor for complex foot ulcers is as high as 15-25% in diabetic patients, as per a global study conducted in 2018.
Efficient wound healing is a major challenge in the case of diabetic wounds/ foot ulcers, pressure ulcers, and venous leg ulcers.
Impaired wound healing greatly impacts physical, psychological, social, and economic aspects for patients, affecting their quality of life, and even calling for amputations in certain difficult cases.
Current Scenario: Frequent surgical debridement, antibiotic dressings, or recombinant growth factor injections are the solutions employed now.
All have limitations ranging from the requirement of skilled medical personnel, secondary antimicrobial resistance, low efficacy and high cost.
The new formulation's performance: On a head-to-head with a marketed product, in-vivo data showed that the two proprietary components of the new formulation have significantly better:
a) Wound healing
b) Collagen deposition in diabetic animals.
We believe it will also be useful in the treatment of other complex wounds like pressure ulcers and burns.
We are inviting licensing interests.
To know more, please reach out to the CCAMP Office of Technology Transfer (#OTT):
📧[email protected]
☎️080 6718 5322
@Taslimarif @DBTIndia @PrinSciAdvOff @kris_sg @BIRAC_2012 @Convatec @MDT_Diabetes @cardinalhealth @SmithNephewPLC @integra_life @JNJNews @MiMedx @Coloplast_WCare @orgoholdingsinc @3M
#TechForLicensing: CCAMP-developed Optidrop technology makes it easier and cheaper to study single cells encapsulated in droplets.
The platform's affordability, live data visualisation, smaller data footprint, and 'closed' system design (preventing external contamination) make OptiDrop a viable benchtop technology for widespread clinical applications.
Optidrop has game-changing downstream applications in #diagnostics, #therapeutics, #agriculture and #animalhealth.
Read more: https://t.co/99xMMbKHIk
The work has been done in collaboration with
@iitmadras and support from @BIRAC_2012, @DBTIndia and Pratiksha Trust of @kris_sg.
We are seeking interest in licensing/co-development from companies and #industry partners.
If you are interested in knowing more, please reach out to the C-CAMP Office of Technology Transfer (#OTT):
📧 [email protected]
☎️080 6718 5322
@Taslimarif @JNJNews @pfizer_news @ZydusUniverse @calico @BoehringerIN @Ginkgo @IVIHeadquarters @PrinSciAdvOff @AIMtoInnovate @NITIAayog @ITBTGoK @meitystartuphub
#TechForLicensing: CCAMP-developed Optidrop technology makes it easier and cheaper to study single cells encapsulated in droplets.
The platform's affordability, live data visualisation, smaller data footprint, and 'closed' system design (preventing external contamination) make OptiDrop a viable benchtop technology for widespread clinical applications.
Optidrop has game-changing downstream applications in #diagnostics, #therapeutics, #agriculture and #animalhealth.
Read more: https://t.co/99xMMbLfxS
The work has been done in collaboration with
@iitmadras with support from @BIRAC_2012
@DBTIndia and Pratiksha Trust of @kris_sg
We are seeking interest in licensing/co-development from companies and #industry partners. If you are interested to know more, please reach out to the C-CAMP Office of Technology Transfer (#OTT):
📧 [email protected]
☎️080 6718 5322
@Taslimarif @JNJNews @pfizer_news @ZydusUniverse @calico @BoehringerIN @Ginkgo
@IVIHeadquarters @PrinSciAdvOff @AIMtoInnovate
@NITIAayog @ITBTGoK @MSH_MeitY
#TechForLicensing: Researchers at CCAMP in collaboration with @DBT_CDFD have successfully developed & tested in mice a novel topical formulation — RegenHeal — that shows significantly accelerated complex wound healing through promoting regeneration of tissues!
The Problem: The risk factor for complex foot ulcers is as high as 15-25% in diabetic patients as per a global study conducted in 2018. Efficient wound healing is a major challenge in the case of diabetic wounds/ foot ulcers, pressure ulcers, and venous leg ulcers. Impaired wound healing greatly impacts physical, psychological, social, and economic aspects for patients, affecting their quality of life, and even calling for amputations in certain difficult cases.
Current Scenario: Frequent surgical debridement, antibiotic dressings, or recombinant growth factor injections are the solutions employed now. All have limitations ranging from the requirement of skilled medical personnel, secondary antimicrobial resistance, low efficacy and high cost.
RegenHeal's performance: On a head-to-head with a marketed product, in-vivo data showed that the two proprietary components of RegenHeal have significantly better:
a) Wound healing
b) Collagen deposition in diabetic animals.
We believe it will also be useful in the treatment of other complex wounds like pressure ulcers and burns.
We are inviting licensing interests.
To know more, please reach out to the C-CAMP Office of Technology Transfer (#OTT):
📧 [email protected]
☎️080 6718 5322
@Taslimarif @DBTIndia @PrinSciAdvOff @kris_sg
@BIRAC_2012 @Convatec @MDT_Diabetes
@cardinalhealth @SmithNephewPLC @integra_life
@JNJNews @MiMedx @Coloplast_WCare @orgoholdingsinc @3M
#TechForLicensing CCAMP developed Optidrop technology brings in new miniaturization possibilities at single-cell resolution to cell interrogation. It combines the power of flow cytometry and droplet microfluidics using an on-chip optical fiber enabled sensing mechanism.
Droplet microfluidics has the potential to revolutionize diagnostics, genomics and drug discovery by bringing high-throughput analysis of single-cell and analytes within reach. But it has been so far largely untapped due to bulky, expensive imaging or flow cytometry sensing platforms. Optidrop will change this.
Optidrop is the world's first droplet cytometer with single-cell resolution for multiplexed fluorescence sensing.
Patent 1 granted in USA, Eurasia. PCT for patent 2 in USA, EP, India
Read more https://t.co/99xMMbKHIk
The work has been done in collaboration with @iitmadras with support from @BIRAC_2012 @DBTIndia
Excited yet? We are inviting licensing interests. If you are interested to know more, please reach out to the C-CAMP Office of Technology Transfer (#OTT):
📧 [email protected]
📞080 6718 5322
@Taslimarif @JNJNews @pfizer_news @ZydusUniverse @calico @BoehringerIN @Ginkgo @IVIHeadquarters @PrinSciAdvOff @AIMtoInnovate @NITIAayog @ITBTGoK @MSH_MeitY @kris_sg
#TechForLicensing A Novel Topical Formulation for treating Pre-cancerous Lesions/Early-stage Skin Cancer in invasive squamous cell carcinoma or SCC, the second most common type of skin cancer, with an estimated 1.8 million cases diagnosed each year worldwide
Problem - SCCs start off as premalignant lesions called Actinic Keratoses (AKs). Global prevalence rate of AK stands at 14% affecting more than 40 million Americans each year. The most used line of treatment for AK is topical application of 5-fluorouracil (5-FU). 5-FU is highly toxic and has serious side effects like erythema or severe redness, pruritus or severe itchiness, crusting and pain.
Solution - A novel topical formulation has been developed and successfully tested by C-CAMP’s Discovery-to-Innovation Accelerator (DIA) program in collaboration with @DBT_CDFD, Hyderabad on xenograft melanoma mice showing significant tumor growth reduction with no toxicity in preliminary in vivo models.
Key properties: This formulation comprises a novel component used alone or combined with 5-FU. The molecule shows potent immunomodulatory and anti-inflammatory activity and significantly improved efficacy over 5-FU alone in vivo.
We are inviting licensing interests. To know more, please reach out to the C-CAMP Office of Technology Transfer (#OTT):
📧 [email protected] 📞080 6718 5322
@Taslimarif @BIRAC_2012 @PrinSciAdvOff
@DBTIndia @kris_sg @abbvie @abcuro @eurofarma @AcrotechBio @ImmuneOnc @cgoncology
#TechForLicensing:
A Novel Topical Formulation for treating Pre-cancerous Lesions/Early-stage Skin Cancer in invasive squamous cell carcinoma or SCC,
This is the second most common type of #SkinCancer, with an estimated 1.8 million cases diagnosed each year worldwide
Problem - SCCs start off as premalignant lesions called Actinic Keratoses (AKs). Global prevalence rate of AK stands at 14% affecting more than 40 million Americans each year. The most used line of treatment for AK is topical application of 5-fluorouracil (5-FU). 5-FU is highly toxic and has serious side effects like erythema or severe redness, pruritus or severe itchiness, crusting and pain.
Solution - A novel topical formulation has been developed and successfully tested by C-CAMP’s Discovery-to-Innovation Accelerator (DIA) program in collaboration with @DBT_CDFD, Hyderabad on syngeneic mice showing significant tumor growth reduction with no toxicity in preliminary in vivo models.
Key properties: This formulation comprises a novel component used alone or combined with 5-FU. The molecule shows potent immunomodulatory and anti-inflammatory activity and significantly improved efficacy over 5-FU alone in vivo.
We are inviting licensing interests. To know more, please reach out to the C-CAMP Office of Technology Transfer (#OTT):
📧 [email protected] 📞080 6718 5322
@PrinSciAdvGoI @rajesh_gokhale @UllasKolthur @CCAMP_India @BIRAC_2012 @PrinSciAdvOff @kiranshaw
@DBTIndia @kris_sg @abbvie @abcuro @eurofarma @TVMohandasPai @DBT_CDFD @prashanthp @AcrotechBio @ImmuneOnc @cgoncology
#Cancer #CancerAwareness #Oncology
#TechforLicensing Researchers at CCAMP in collaboration with @DBT_CDFD Hyderabad have successfully developed and tested in mice a novel topical formulation RegenHeal that shows significantly accelerated complex wound healing through promoting regeneration of tissues.
The Problem: The risk factor for complex foot ulcers is as high as 15-25% in diabetic patients as per a global study conducted in 2018. Efficient wound healing is a major challenge in case of Diabetic wounds/ foot ulcers, Pressure ulcers, Venous leg ulcers. Impaired wound healing greatly impacts physical, psychological, social, and economic aspects for patients, affecting their quality of life, even calling for amputations in certain difficult cases.
Current Scenario: Frequent surgical debridement, antibiotic dressings, or recombinant growth factor injections are the solutions employed now. All have limitations ranging from requirement of skilled medical personnel, secondary antimicrobial resistance, low efficacy and high cost.
RegenHeal's performance: On a head to head with a marketed product, in vivo data showed that the 2 proprietary components of RegenHeal have significantly better
a) Wound healing
b) Collagen deposition in diabetic animals.
We believe it will also be useful for treatment of other complex wounds like pressure ulcers and burns.
We are inviting licensing interests. To know more, please reach out to the C-CAMP Office of Technology Transfer (#OTT): 📧 [email protected]
📞080 6718 5322
@Taslimarif @DBTIndia @PrinSciAdvOff @kris_sg @BIRAC_2012 @Convatec @MDT_Diabetes @cardinalhealth @SmithNephewPLC @integra_life @JNJNews @MiMedx @Coloplast_WCare @orgoholdingsinc @3M
#TechForLicensing A Novel Topical Formulation for treating Pre-cancerous Lesions/Early-stage Skin Cancer in invasive squamous cell carcinoma or SCC, the second most common type of skin cancer, with an estimated 1.8 million cases diagnosed each year worldwide
The problem - SCCs start off as premalignant lesions called Actinic Keratoses (AKs). Global prevalence rate of AK stands at 14% affecting more than 40 million Americans each year. The most used line of treatment for AK is topical application of 5-fluorouracil (5-FU). 5-FU is highly toxic and has serious side effects like erythema or severe redness, pruritus or severe itchiness, crusting and pain.
Solution - A novel topical formulation has been developed and successfully tested by C-CAMP’s Discovery-to-Innovation Accelerator (DIA) program in collaboration with @DBT_CDFD, Hyderabad on syngeneic mice showing significant tumor growth reduction with no toxicity in preliminary in vivo models.
Key properties - This formulation comprises a novel component used alone or combined with 5-FU. The molecule shows potent immunomodulatory and anti-inflammatory activity and significantly improved efficacy over 5-FU alone in vivo.
We are inviting licensing interests. To know more, please reach out to the C-CAMP Office of Technology Transfer (#OTT):
📧 [email protected] 📞080 6718 5322
@Taslimarif @BIRAC_2012 @PrinSciAdvOff
@DBTIndia @kris_sg @abbvie @abcuro @eurofarma @AcrotechBio @ImmuneOnc @cgoncology
#TechForLicensing #PatentApplication CCAMP and Institute of Plasma Research (IPR) have jointly filed a patent for their "Cold Atmospheric Plasma-Based (CAP) Air Disinfection Device"
The solution addresses limitations of the existing technologies for air purification and is
capable of:
📌Neutralizing pathogens
on top of
📌Trapping/removing PM 2.5 and PM 10 particles rendering improved ambient air quality
📌Faster disinfection and purification of air covering entire range of pollutants, pathogens, SPM and VoCs.
Advantages of design:
📌The device has been validated on the ESKAPE range of bacterial pathogens, fungal pathogens and viral organisms by an independent NABL-accredited lab.
📌Device can be customized as
stand-alone as well as an attachment with existing filtration devices and AHU systems.
📌Plasma-Clean is scalable as the cartridge is modular and product can be scaled suited for the application area.
Plasma Clean is the nextgen in air purification.
If you are interested to know more, please reach out to the C-CAMP Office of Technology Transfer (#OTT):
📧 [email protected] 📞080 6718 5322
@Taslimarif @BIRAC_2012 @PrinSciAdvOff @DBTIndia @kris_sg @honeywell @Dyson @BlueairUS @Bry_Air @IQAir @BlueStarLtd @GodrejGroup @BreatheEasyLabs
Most Popular Users
Elon Musk 
@elonmusk
241.6M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
89.9M followers
Taylor Swift
@taylorswift13
83.8M followers
Lady Gaga
@ladygaga
75.3M followers
Virat Kohli
@imvkohli
73.1M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.2M followers
Bill Gates
@billgates
65M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers